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The present status of cancer chemother-
apy can be reviewed in light of selected basic 
principles with an acknowledgement of the role 
of established chemotherapeutic agents. Four 
chemotherapeutic agents recently approved for 
clinical use and their impact when used in com-
bination regimens should be examined. Several 
important concepts influencing chemotherapy 
in the 1980s include the use of chemotherapy 
in the adjuvant setting, the use of hormonal re-
ceptor data in planning therapy, and the use of 
in vitro tests on tumor specimens to predict tu-
mor sensitivity to cancer chemotherapy drugs 
(prior to administration of these potentially toxic 
drugs to a particular patient). Lastly the reader is 
cautioned about the potential of long-term com-
plications with certain chemotherapy agents, 
especially in those patients who have had com-
plete or extended partial remissions. 
Review 
The modern era of cancer chemotherapy 
began approximately 40 years ago when nitro-
gen mustard , a derivative of the mustard gases 
used in the World Wars, was demonstrated to 
cause regression of lymphomatous tumors ini-
tially in studies involving mice and later man. 
Since that time a variety of chemicals and natu-
ral products have been synthesized (or isolated) 
and subjected to various screening programs in 
an attempt to identify potential clinically-effec-
tive drugs. Today there are approximately 30 
drugs that have been approved and deemed 
valuable in the treatment of various human can-
cers. 1 These agents can be categorized into six 
major classes (Table 1 ). 
The development of these diverse agents 
which effect various critical biochemical steps 
or processes has occurred during a period in 
which there have been rapid and significant 
gains in our understanding of the molecular bi-
ology of the cell. Concomitantly, there has been 
an increased understanding of tumor cell biol-
ogy which has markedly influenced the way 
cancer chemotherapy drugs are used today. 
Cell kinetic studies in animal models have dem-
onstrated that a single malignant cell can multi-
ply within a host animal to eventually kill the 
host. Thus curative therapeutic approaches 
must aim to eradicate every malignant cell . 
Studies with anticancer agents in animal models 
have shown that chemotherapy kills cells in a 
first-order kinetic manner, ie , with each treat-
ment a constant percentage (rather than a con-
stant number) of cells is killed . These generally 
accepted "principles" have provided support 
for the aggressiveness now used in many of the 
multiagent chemotherapy regimens and have 
formed the basis for adjuvant and maintenance 
chemotherapy. 2 
Multiagent , or combination chemother-
apy, the major approach used in advanced can-
cer today, has been influenced by a better com-
prehension of the cell cycle . Thus it is 
recognized that certain drugs act on cells only 
in a specific phase of the cell cycle (the life 
cycle through which a cell passes from its origin 
when formed from the mother cell to the point at 
which it in turn divides into daughter cells) while 
other drugs are non-cycle specific, being able 
to affect cells regardless of where they are in 
the cell cycle, including cells not actively repli-
cating . The recognition of this concept has 
been utilized in designing effective combination 
regimens which aim at affecting cells in different 
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TABLE 1 
Classification of Cancer Chemotherapy Agents 
phases of the cell cycle to obtain the maximum 
therapeutic effect. 
Alkylating Agents 
Mechlorethamine (Mustargen) 
Cyclophosphamide (Cytoxan) 
Chlorambucil (Leukeran) 
Melphalan (Alkeran) 
Triethylenethiophosphoramide (thiotepa) 
Nitrosoureas 
(BCNU or Carmustine) 
(CCNU or Lomustine) 
(5-(3 ,3-Dimethyl-1-triazene)-imidazole-4-
carboxamide) 
(Dacarbazine or DTIC) 
Antimetabolites 
Methotrexate 
5-Fluorouracil (Fluorouracil, Adrucil) 
Cytosine arabinoside (ara-C or cytosar) 
6-mercaptopurine (Purinethol) 
6-thioguanine (thioguanine) 
Antibiotic 
Dactiomycin (actinomycin D. (Cosmergen)) 
Mithromycin (Mithracin) 
Doxorubicin (Adriamycin) 
Daunorubicin (Daunomycin) 
Mitomycin C (Mutamycin) 
Bleomycin (Blenoxane) 
Natural Products 
Vinblastine (Velban) 
Vincristine (Oncovin) 
L-Asparaginase (E.lspar) 
Miscellaneous Agents 
o,p '-DDD (Mitotane (Lysodren)) 
Hydroxyurea (Hydrea) 
Procarbazine (Matulane) 
The success of chemotherapy in the man-
agement of human cancer can be seen in Ta-
bles 2 and 3.2 Table 2 demonstrates that in at 
least seven tumor types, chemotherapy now of-
fers either cure or at the very least a significant 
prolongation of life. While actual cure has not 
been achievable for the five tumors listed in 
Table 3 , there nevertheless has been a demon-
strated increased survival and palliation. For the 
remaining tumor types not listed, including the 
relatively frequent cancers such as carcinoma 
of the lung and large bowel , cure and palliation 
are less likely at present. With the development 
of new agents, it is hoped that more effective 
combination regimens will be created to im-
prove survival in these currently less responsive 
tumors as well. 
Update 
Over the past several years there have 
been four new agents introduced clinically that 
are now not only approved for non-investiga-
tional use but. also occupy important roles in 
cancer chemotherapy already. The increasing 
use of all four drugs necessitates a basic under-
standing of them by every physician participat-
ing in the care of a particular cancer patient. 
Cis-platinum diamine dichloride (Cisplatin, Platinol) Doxorubicin (Adriamycln) 
Hormones 
Estrogens 
Androgens 
Progestational Steroids 
Adrenal Steroids 
Antiestrogen tamoxifen citrate (Nolvadex) 
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Perhaps the most important new agent is 
Adriamycin . This drug and the closely related 
drug Daunorubicin (Daunomycin) are anthracy-
clene derivatives obtained as fermentation 
products from Streptomyces (Fig 1 ). These 
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TABLE 2 
Cure or Increased Survival 
Type of Cancer 
Gestational trophoblastic tumors 
Chemotherapy 
Methotrexate, dactinomycin, 
Results 
70% cured 
vinblastine 
Burkitt 's tumor 
Testicular tumors (nonseminoma) 
Cyclophosphamide (many others) 
Dactinomycin , 
50% cured 
70-80% respond; 2-3% cured 
Methotrexate chlorambucil, 
Bleomycin , Cis-platinum diamine 
dichloride 
Wilms ' tumor Dactinomycin plus vincristine with 30-40% cured 
surgery and radiotherapy 
Neuroblastoma Cyclophosphamide with surgery 5% cured 
and /or radiotherapy 
Acute lymphoblastic leukemia Daunorubicin, prednisone , vincristine, 90% remission ; 70% survive beyond 
6-mercaptopurine, Methotrexate, 5 years 
BCNU 
Hodgkin's disease, stage 1118 and IV MOPP, ABVD 70% respond; 40% survive beyond 
5 years 
(Note: Adapted from I H Krakoff , Cancer Chemotherapeutic Agents, Ca-A Cancer Journal of Clinicians, 27, 1977, 132.) 
(By Permission) 
drugs are classified as antibiotic cancer chemo-
therapy agents. 
The mechanism of action of both drugs is 
believed to be via inhibition of DNA synthesis. 
These agents are known to interact with DNA, 
eventually intercalating into the nucleic acid he-
lix leading to uncoiling of the DNA and inhibiting 
both RNA and DNA synthesis. Both agents are 
maximally effective during the S phase of the 
cell cycle, but inhibition can occur at all stages 
of the cell cycle, particularly at higher concen-
trations. 3 
The pharmacology of these drugs is still 
somewhat incomplete. At present they are used 
only intravenously. The major site of metabolism 
is in the liver by both soluble and microsomal 
enzymes. Less than 1 0% of the drug is ex-
creted in the urine. Because of the importance 
of liver metabolism, the dose of Adriamycin is 
reduced in the presence of hepatic dysfunction . 
No drug adjustments are made for renal dys-
function . The total dose should not exceed 
550-600 mg/M 2 . 2 ·3 
Both drugs have similar side effects and 
toxicities including: 1) gastrointestinal (nausea, 
vomiting, diarrhea, and stomatitis); 2) hemato-
logic (leukopenia with a nadir at 1 0-1 5 days, 
and thrombocytopenia); 3) dermatologic (alo-
pecia, local phlebitis and necrosis if extrava-
sated); 4) cardiac (by far the most serious tox-
icity with these drugs is manifested as 
congestive heart failure due to a diffuse car-
diomyopathy). 
The major indications for Daunorubicin 
(Daunomycin) have been in acute granulocytic, 
and in lymphocytic, leukemia . In contrast, 
Doxorubicin (Adriamycin) has been active not 
only in leukemia but also in bladder cancer, 
breast cancer , bronchiogenic cancer, Hodgkin 
and non-Hodgkin lymphoma , thyroid cancer 
and sarcomas in general. 
Bleomycin (Blenoxane) 
Bleomycin, also of the antibiotic class of 
chemotherapy agents isolated from Strepto-
myces, is actually a mixture of several similar 
polypeptides, each having a molecular weight 
of approximately 1500. The A2 peptide is the 
major compound present in the commercial 
preparation and is believed to be the active 
component (Fig 2). 
The mechanism of action of Bleomycin 
appears to be by scission of double-stranded 
DNA, resulting in fragmentation of DNA, in turn 
causing inhibition of DNA synthesis . This drug 
appears to block cells at the G2 /M interphase 
of the cell cycle. 
The pharmacology of this drug in vivo has 
been limited by the fact that the drug is a mix-
ture of several compounds. Following adminis-
tration, it disappears rapidly from the plasma 
with an estimated half life of 1 5-60 minutes. 
Since the dq..1g is known to be excreted primarily 
via the kidneys, the dose should be reduced in 
the presence of renal dysfunction . Bleomycin is 
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Bleomycin A 
Fig. 2. 
degraded mainly by the action of ani-
monopeptidase which is present in tumor cells, 
liver and kidney. It is absent from the skin and 
lungs, two tissues which are particularly suscep-
tible to damage from this drug. Bleomycin is ad-
ministered either intravenously, intramuscular-
ly, or subcutaneously.2•3 
ing to fibrosis. The occurrence of toxicity need 
not be related to the cumulative dose although it 
is more frequent with a total dose greater than 
250 units/M2 or a single dose greater than 25 
units/M2 . The risk is increased particularly in in-
dividuals more than 50 years old who may have 
prior lung disease or may have previously been 
treated with radiation therapy. Pulmonary func-
tion tests have not been of value in predicting 
pulmonary toxicity. A cumulative dose of 400 
units is the accepted maximum dose. Since the 
drug is a polypeptide, a potential side effect 
with this agent is anaphylaxis. Fever and chills 
As noted above, Bleomycin toxicity in-
cludes skin toxicity (such as hyperpigmentation, 
thickening, ulceration, rash, alopecia, or nail 
changes) and pulmonary toxicity. This last se-
vere toxic finding may be present as pneumo-
nitis with dyspnea, rAles and infiltrate progress-
Type of Cancer 
Prostate carcinoma 
Breast carcinoma 
Chronic lymphocytic leukemia 
Lymphosarcoma 
Acute myeloblastic leukemia 
TABLE 3 
Palliation and Prolongation of Life 
Chemotherapy 
Estrogens, castration, cyclophos-
phamide 
Androgens, estrogens, alkylating 
agents, 5-fluorouracil, vincristine, 
prednisone, Methotrexate, 
Adriamycin 
Prednisone, alkylating agents 
Prednisone, alkylating agents 
Cytosine arabinoside and 
thioguanine 
Results 
70% respond with some prolongation 
of life 
60-80% respond with probable 
prolongation of life 
50% respond with probable prolonga-
tion ofme 
50% respond with probable 
prolongation of lifa 
65% remission with prolongation 
of life 
(Note: Adapted from IH Krakoff, Cancer Chemotherapeutic Agents, Ca-A Cancer Journal of Clinicians, 27, 1977, 132.) 
(By Permission) 
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cis-Diamminedichloroplatinum 
Fig. 3. 
occur in 20-30% of patients. The possibility of 
hypersensitivity is particularly a problem in lym-
phoma. Nausea and vomiting may also occur 
with administration of Bleomycin . One toxic 
manifestation notably absent with this chemo-
therapeutic agent is the lack of hematologic tox-
icity making this drug especially appealing for 
combination chemotherapy. 
The major indications for Bleomycin have 
been in lymphomas (Hodgkin and non-Hodg-
kin}, testicular tumors, and squamous cell carci-
noma of the head and neck. Other indications 
are less clear at this time. 
Cis-Diamminedichloroplatlnum (Cis-plati-
num, Platinol) 
This agent is a heavy metal coordination 
complex of platinum containing two ammonia 
groups and two chlorines in the Cis con-
formation (Fig 3). It is listed as a random syn-
thetic type of chemotherapeutic drug . The 
mechanism of action appears to be through in-
hibition of DNA synthesis thought to result from 
both interstrand and intrastrand crosslinks in 
DNA. It appears to be cycle non-specific. 
Cis-platinum is administered in an intra-
venous solution usually in an infusion from 1 5 
minutes to eight hours. Following administra-
tion, plasma levels of the drug show a biphasic 
pattern of decay with an initial half life of 2 5 to 
50 minutes and a terminal half life of 58 to 72 
hours. Studies of distribution have demon-
strated the greatest uptake in the excretory or-
gans, ovary, and uterus. More than 90% of the 
platinum following administration is protein 
bound. Cis-platinum is excreted mainly via the 
urine. This drug should be used with caution or 
even withheld if renal dysfunction occurs with a 
creatinine clearance of <60 ml/min . An at-
tempt has been made to minimize renal toxicity 
secondary to Cis-platinum administration by 
hydrating the patient prior to drug receipt, giving 
diuretics and infusing chemotherapy slowly. 
The renal toxicity appears to be dose re-
lated. Close follow-up of BUN, creatinine, and 
uric acid , and particularly creatinine clearance 
is advisable. Other side effects include ototoxi-
city, relatively frequent nausea and vomiting, 
leukopenia, thrombocytopenia, and anemia . 
Anaphylactic reactions have been described in 
no more than 1 % of the patients given this 
drug. Peripheral neuropathies and loss of taste 
are less common side effects. 4 This drug ap-
pears to be active in testicular tumors, ovarian 
cancer, bladder cancer, and head and neck 
cancer. 
Tamoxifen Citrate (Nolvadex) 
Tamoxifen is a synthetic non-steroidal trip-
henylethylene derivative that has been demon-
strated to have potent anti-estrogen activity in 
several mammalian species. It is classified as a 
hormonal type of chemotherapy agent (Fig 4 ). 
The mechanism of action appears to involve in-
hibition of estrogen binding to cyctoplasmic es-
trogen receptors present in sensitive cells such 
as breast cancer. It is believed that following 
binding to the receptor, estradiol-estrogen re-
ceptor formation is blocked. Since this receptor 
is necessary for activation of certain nucleic 
acid processes, the hormonal response of these 
cells is blocked . 
This drug is given orally in 1 Omg tablets. 
Following oral administration , peak levels occur 
within four to seven hours. The initial half life is 
estimated to be from seven to 1 4 hours. Pro-
Tamoxif en 
Fig. 4. 
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longed blood levels may therefore occur. This is 
thought to be due to concentration and excre-
tion into the bile tract with reabsorption through 
the enterohepatic circulation. 
Toxicity due to antiestrogenic actions in-
clude hot flashes, vaginal bleeding, menstrual 
irregularities, and pruritis vulvae. Non-specific 
gastrointestinal side effects have been de-
scribed such as nausea, vomiting and distaste 
for food . Other toxic manifestations may include 
fluid retention, hypocalcemia, ahd dizziness. 5 
The major indication at present is in pallia-
tive treatment of advanced metastatic breast 
carcinoma. The use of this drug in estrogen-re-
ceptor positive premenopausal women with 
breast cancer is currently being evaluated by 
the National Surgical Adjuvant Breast Project. 
New Combinations 
The addition of these new agents has 
made possible new combinations taking into 
account not only the principle of cell cycle and 
cell kinetics suggested earlier, but also permit-
ting modification of toxicity since many of these 
new agents have toxicity different from many of 
the standard agents in chemotherapy. For ex-
ample, Bleomycin and Tamoxifen have essen-
tially no hematologic toxicity and are attractive 
to use in combination with agents that might 
cause marked hematologic toxicity. Two partic-
ularly interesting new combinations include the 
ABVD regimen (Adriamycin, Bleomycin, Vin-
blastine and 5-(3, 3-Dimethyl-1-triazene)~imida-
zole-4-carboxamide) used in Hodgkin disease 
and the Cis-platinum-Bleomycin-Vinblastine 
combination used in testicular cancer.6 
The ABVD combination has been shown 
to be approximately equally active to the MOPP 
combination (Mechlorethamine + Oncovin 
+prednisone+procarbazine) used in the treat-
ment of advanced Hodgkin disease. More im-
portantly, there appears to be little cross resis-
tance of the ABVD regimen with the MOPP 
combination making possible a suitable alterna-
tive treatment for MOPP failures. The combined 
use of Bleomycin and Adriamycin has also been 
shown to be active in some recent combinations 
used in non-Hodgkin lymphomas as well. 7 
In testicular cancers the contribution of 
these new agents (Bleomycin and particularly 
Cis-platinum) is even more impressive. While 
several active agents have been available for 
many years including Methotrexate, Acti-
nomycin D, and Mithramycin , the percentage of 
complete remissions was consistently 30% or 
less with no prolonged survivals. The combina-
tion of Cis-platinum-Vinblastine-Bleomycin has 
resulted in complete remission rates of 70% or 
greater with an increased percentage of pro-
longed survivors. 8 The evolution of chemother-
apy in the treatment of testicular cancer with 
first the addition of Bleomycin and later the ad-
dition of platinum illustrates the point made ear-
lier that as new agents are introduced in combi-
nation with other effective agents, there is hope 
that still more effective combinations will be 
found in the treatment of other cancers as well. 
Adjuvant Chemotherapy 
Adjuvant chemotherapy is usually defined 
as the use of chemotherapy together with sur-
gery and/or radiotherapy. As suggested earlier, 
cell kinetics provide a rationale for the use of 
adjuvant chemotherapy. Following removal of a 
tumor mass and a curative resection, the cell 
number should be reduced dramatically. When 
the cell number is relatively low, tumor cells are 
more likely to be actively growing and dividing. 
Since most chemotherapeutic drugs will kill 
cancer cells actively "in phase" in the cell 
cycle, it should follow that the smaller the tumor 
mass, the larger the growth fraction and the 
more likely the cells are to respond to cytotoxic 
drugs. The fact that only one cell is needed to 
theoretically kill the host, and the fact that 
chemotherapeutic drugs kill in a first-order ki-
netic manner, further supports the rationale for 
chemotherapy in the adjuvant setting . A number 
of experimental studies using mouse and rat tu-
mor models have substantiated the value of ad-
juvant chemotherapy in prolonging survival. 9 
Clinical trials have now demonstrated a 
definite role for adjuvant chemotherapy in at 
least delaying the occurrence of metastases in 
premenopausal patients with breast cancer. It is 
still somewhat early to evaluate the overall ef-
fect on survival, although it does not appear to 
be as promising as originally hoped. Two regi-
mens have been used in extensive adjuvant 
studies in breast cancer in this country and 
abroad. The American study has utilized the al-
kylating agent L-phenylalanine mustard, while 
the European study from Italy has utilized the 
combination of Cyclophosphamide, Methotrex-
ate and 5-fluorouracil . Both studies have dem-
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onstrated a definite role in premenopausal can-
cer, although the role in _postmenopausal 
cancer is somewhat less clear. 1 0 
On osteogenic sarcoma there has been a 
dampening of the original enthusiasm for adju-
vant chemotherapy. The initial regimens used 
during the past five years have included the use 
of Adriamycin with and without other agents 
and the use of high-dose Methotrexate. In these 
studies there has been the suggestion that 
again metastases may be delayed; but in this 
case it appears much less likely that any overall 
improvement of survival has resulted. 9 
For other tumor types the role of adjuvant 
chemotherapy . at present remains much less 
clear. There is, however, the hope that with 
newer agents resulting in more effective combi-
nations, there will be increased effectiveness of 
these drugs used early in the course of the dis-
ease with the anticipation that not only the onset 
of metastatic lesions will be delayed but also 
that survival time will be prolonged. 
Receptor Status 
Over the past several years there has 
been widespread acceptance by the medical 
and surgical community of the importance of 
obtaining breast tumor specimens at the time of 
surgery for assessmer,t of estrogen as well as 
possibly other hormonal receptors. 11 The estro-
gen receptor assay has been shown to have a 
positive correlation greater than 65% with re-
sponse to hormonal therapy in several large 
studies recently completed. Fwrthermore, pa-
tients with estrogen~receptor negative tumors 
appear not to respond to hormonal therapy. The 
most important impact of this receptor data is 
that approximately a third of all breast patients 
with metastasis are estimated not to respond to 
hormonal therapy. With the use of the hormonal 
· receptor assays, patients who are estrogen-re-
ceptor negative may be spared ineffective ther-
apy and may be begwn on more effective cyto-
toxic chemotherapy at an earlier point . 
Less clear is the importance of estrogen-
receptor negative status in premenopausal 
patients. Recently it has been suggested in a 
retrospective study conducted at the National 
Cancer Institute that estrogen-receptor negative 
patients may actually respond better to chemo-
therapy than estrogen-receptor positive 
patients. This study, however, has been con-
tradicted by yet another retrospective study. At 
th~ present time prospective studies are needed 
to clarify this hypothesis, and no recommenda-
tions can be made. 12 
Prediction of Drug Response 
For many years there has been the hope 
that one could test tumor cells, much as one 
tests bacteria cultured from an infected patient, 
thereby making a more rational choice of the 
agent or agents to be used. To some extent this 
approach has already been adopted in breast 
cancer where the presence or absence of estro-
. gen receptors in the tumor specimen from a 
particular patient may determine whether hor-
monal therapy will be used. Recently a new 
method was demonstrated which permits tumor 
cells, obtained from specimens at the time of 
surgery, to be cultured so that drugs may be 
tested for possible effect. While only a limited 
number of cases have been studied at the pres-
ent time , data in multiple myeloma and ovarian 
cancers suggest that the possibility exists that 
indeed a predictive test may be possible, 13 
thereby at the very least preventing the use of 
ineffective cytotoxic drugs and possibly deter-
mining effective drugs that may be used in the 
treatment of the individual patient. Again re-
search will be conducted in the 1980s which 
will further clarify the usefulness of this new 
method. 14 
Long-Term Effects of Chemotherapy 
While the immediate and idiosyncratic ef-
fects of the various chemotherapeutic agents 
have been well known, it is now clear that some 
of these drugs, particularly the alkylating agents 
and those drugs that intercalate into DNA, may 
result in the development of secondary neo-
plasms. These usually occur four to five years 
after the initial chemotherapy has been com-
pleted . 15 The implication is that the very patients 
- who have been ''cured'' by chemotherapy have 
then gone on to develop neoplasms secondary 
to the initial chemotherapy. This has now been 
seen in an increasing number of chemore-
sponsive tumors; eg with the use of alkylating 
agents in multiple myeloma or with alkylating 
agents with or without radiotherapy in Hodgkin 
disease. 
The effects of radiotherapy have long 
been known to be associated with secondary 
neoplasms so that patients receiving radio-
therapy and chemotherapy with agents which 
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interfere with the DNA structure may be espe-
cially at risk. With the development of more ef-
fective combinations, it is hoped that some of 
the agents responsible for these catastrophic 
toxicities may be removed and replaced by 
·' non-carcinogenic'' drugs. 
Lastly, there will be a need to review the 
use of certain potentially ''carcinogenic'' agents 
in adjuvant regimens, especially in those pa-
tients who may indeed have been cured by sur-
gery. With more experience it is hoped that the 
more toxic agents may be removed from these 
combinations as well. 
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